You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

4885 Results
Guidelines and Advice
Nov 2017
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant, Palliative
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Adjuvant, Palliative
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
ODB - General Benefit
    procarbazine
ODB - General Benefit
    prednisone
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade, 
Multiple Myeloma
Intent: Palliative

Pages